 Hematologic Neoplasms
"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Descriptor ID |
D019337
|
| MeSH Number(s) |
C04.588.448 C15.378.400
|
| Concept/Terms |
Hematologic Neoplasms- Hematologic Neoplasms
- Hematologic Malignancy
- Neoplasms, Hematologic
- Hematologic Neoplasm
- Neoplasm, Hematologic
- Hematological Neoplasms
- Hematological Neoplasm
- Neoplasm, Hematological
- Neoplasms, Hematological
- Malignancies, Hematologic
- Malignancy, Hematologic
- Hematologic Malignancies
- Hematological Malignancies
- Hematological Malignancy
- Malignancies, Hematological
- Malignancy, Hematological
Hematopoietic Neoplasms- Hematopoietic Neoplasms
- Neoplasms, Hematopoietic
- Hematopoietic Neoplasm
- Neoplasm, Hematopoietic
- Hematopoietic Malignancies
- Hematopoietic Malignancy
- Malignancies, Hematopoietic
- Malignancy, Hematopoietic
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".
This graph shows the total number of publications written about "Hematologic Neoplasms" by people in this website by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 2002 | 1 | 2 | 3 | | 2004 | 0 | 1 | 1 | | 2006 | 0 | 3 | 3 | | 2007 | 2 | 1 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 3 | 4 | | 2010 | 7 | 0 | 7 | | 2011 | 7 | 2 | 9 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 1 | 3 | | 2014 | 4 | 1 | 5 | | 2015 | 7 | 2 | 9 | | 2016 | 7 | 5 | 12 | | 2017 | 7 | 1 | 8 | | 2018 | 7 | 2 | 9 | | 2019 | 2 | 1 | 3 | | 2020 | 5 | 0 | 5 | | 2021 | 6 | 0 | 6 | | 2022 | 3 | 0 | 3 | | 2023 | 11 | 0 | 11 | | 2024 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles.
-
Weisse CS, Melekis K, Cheng A, Konda AK, Major A. Mixed-Methods Study of End-of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings. JCO Oncol Pract. 2024 Jun; 20(6):779-786.
-
Katsnelson EN, Spengler A, Domenico J, Couts KL, Loh L, Gapin L, McCarter MD, Tobin RP. Dysfunctional states of unconventional T-cell subsets in cancer. J Leukoc Biol. 2024 01 05; 115(1):36-46.
-
Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, Gill SI. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med. 2023 09 20; 15(714):eadi1145.
-
Lee TD, Aisner DL, David MP, Eno CC, Gagan J, Gocke CD, Guseva NV, Haley L, Jajosky AN, Jones D, Mansukhani MM, Mroz P, Murray SS, Newsom KJ, Paulson V, Roy S, Rushton C, Segal JP, Senaratne TN, Siddon AJ, Starostik P, Van Ziffle JAG, Wu D, Xian RR, Yohe S, Kim AS. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Adv. 2023 08 22; 7(16):4599-4607.
-
Kent A, Crump LS, Davila E. Beyond a? T cells: NK, iNKT, and ?dT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023; 14:1202950.
-
Pillsbury CE, Dougan J, Rabe JL, Fonseca JA, Zhou C, Evans AN, Abukharma H, Ichoku O, Gonzalez-Flamenco G, Park SI, Aljudi A, DeRyckere D, Castellino SM, Rafiq S, Langermann S, Liu LN, Henry CJ, Porter CC. Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun. 2023 07; 3(7):1248-1259.
-
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
-
DiNardo CD, De Botton S, Pollyea DA, Stone RM, Altman JK, Fathi AT, Limsakun T, Liang M, Choe S, Hossain M, Tron AE, Meng Q, Kapsalis SM, Pandya SS, Stein EM. Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. Am J Hematol. 2023 09; 98(9):E233-E236.
-
Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, Schischlik F, Ongkeko M, Wang Y, Shahani S, Cullinane A, Smith H, Kane E, Little L, Chen D, Fry TJ, Shalabi H, Wang HW, Satpathy A, Lozier J, Shah NN. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023 06; 11(6).
-
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|